Intravenous artesunate for transfusion-transmitted plasmodium vivax malaria in a preterm neonate.

Abstract

Transfusion-transmitted malaria (TTM) in neonates is rare. TTM can occur in both endemic and nonendemic areas because the current tests used to screen the donor blood for malaria are unreliable when there is low parasitemia. Malaria must be considered as an important differential diagnosis for neonatal sepsis after exchange transfusion. Management strategy in TTM in the neonatal period is not standardized; exchange transfusion is often considered. We used intravenous artesunate in a case of severe malaria caused by Plasmodium vivax in a 30-week preterm neonate after packed red blood cell transfusion on day 19 of life. This is the first clinical report of parenteral artesunate successfully used in the neonatal period. We emphasize the need for further investigation of the safety and efficacy of intravenous artesunate in the treatment of severe neonatal malaria.

• Authors: Gowda Parameshwar Prashanth, Mahesh B Maralihalli, Praveen S Bagalkot, Suhas N Joshi
• Journal: Pediatrics (Pediatrics) Vol. 130 Issue 3 Pg. e706-9 (Sep 2012) ISSN: 1098-4275 [Electronic] United States
• PMID: 22891231 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antimalarials
• Artemisinins
• Artesunate

Topics

• Antimalarials (administration & dosage)
• Artemisinins (administration & dosage)
• Artesunate
• Female
• Humans
• Infant, Newborn
• Infant, Premature
• Infant, Premature, Diseases (drug therapy)
• Infusions, Intravenous
• Malaria, Vivax (drug therapy, transmission)
• Transfusion Reaction